Eight presentations on antibiotic ceftobiprole providing further evidence for its activity against methicillin-resistant Staphylococcus aureus (MRSA) and other clinically relevant pathogens ...
Allschwil, Switzerland, September 28, 2023 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe...
Seeking approval for Staphylococcus aureus bacteremia (SAB), acute bacterial skin and skin structure infections (ABSSSI), and community-acquired bacterial pneumonia (CABP)NDA eligible for Priority...
Basilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiprole
Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, reported today that data from the successfully completed phase 3 ERADICATE study1, evaluating ceftobiprole in the treatment of adult patients with bacterial bloodstream infections caused by Staphylococcus aureus, (SAB), have been presented at the scientific conference, IDWeek 2022, which took take place in Washington, D.C. from 19 to 23 October.
Basel/Allschwil, Switzerland, July 12, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company, announced today that its distribution partner for Latin America,...
Ceftobiprole met primary and secondary efficacy endpoints Basilea plans to submit a New Drug Application (NDA) in the U.S. around year end 2022 Ad hoc announcement pursuant to Art. 53 LR Basel,...
Basilea Pharmaceutica Ltd. (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, announced today the completion of patient enrolment into the phase 3 ERADICATE study1. This study is investigating ceftobiprole in the treatment of patients with complicated bloodstream infections caused by Staphylococcus aureus, also referred to as Staphylococcus aureus bacteremia (SAB). ERADICATE reached its target enrolment of 390 patients.
Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today that it has entered into an agreement with Moscow-based pharmaceutical company JSC Lancet for the distribution of Basilea’s antibiotic Zevtera® (ceftobiprole medocaril) in Russia, as well as in the other countries of the Eurasian Economic Union.
According to Coherent Market Insights, the global methicillin-resistant Staphylococcus aureus (MRSA) drugs market is estimated to be valued at US$ 922.2 million in 2018, and is projected to exhibit a CAGR of 4.1% over the forecast period (2018–2026).